Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E16.84 EPS (ttm)16.91 Insider Own0.10% Shs Outstand216.84M Perf Week-2.70%
Market Cap61.75B Forward P/E12.65 EPS next Y22.52 Insider Trans-14.06% Shs Float214.71M Perf Month3.99%
Income3.70B PEG2.68 EPS next Q5.00 Inst Own88.90% Short Float0.88% Perf Quarter-10.55%
Sales11.45B P/S5.39 EPS this Y10.30% Inst Trans-1.36% Short Ratio1.07 Perf Half Y-10.50%
Book/sh56.05 P/B5.08 EPS next Y7.31% ROA17.00% Target Price321.72 Perf Year10.70%
Cash/sh22.57 P/C12.61 EPS next 5Y6.29% ROE32.20% 52W Range223.02 - 333.65 Perf YTD0.41%
Dividend- P/FCF16.27 EPS past 5Y27.40% ROI21.00% 52W High-15.00% Beta0.78
Dividend %- Quick Ratio2.30 Sales past 5Y17.80% Gross Margin87.10% 52W Low27.16% ATR5.70
Employees7400 Current Ratio2.60 Sales Q/Q1.20% Oper. Margin45.00% RSI (14)52.88 Volatility1.61% 1.86%
OptionableYes Debt/Eq0.54 EPS Q/Q-20.60% Profit Margin32.30% Rel Volume0.84 Prev Close284.75
ShortableYes LT Debt/Eq0.54 EarningsJan 26 BMO Payout0.00% Avg Volume1.77M Price283.60
Recom2.00 SMA202.00% SMA500.25% SMA200-1.01% Volume1,054,255 Change-0.40%
Feb-07-17Upgrade Citigroup Neutral → Buy
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Feb-24-17 07:35AM  Ring the Register With These Upcoming Spinoffs
Feb-23-17 05:06PM  Teva Is Expected to See a Fall in Its Profit Margins in 2017
08:02AM  Here's Why Celgene's Latest Drug Is So Exciting at Motley Fool
Feb-22-17 09:15AM  Did Biogen Inc. Shoot Itself in the Foot? at Motley Fool
Feb-21-17 03:40PM  Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A at
Feb-20-17 10:30AM  Celgene MS Drug Reports Positive Phase 3 Data at Investopedia
08:24AM  3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter at Motley Fool
07:37AM  This Keeps Driving Sanofis Growth
07:36AM  Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment
Feb-19-17 11:41AM  Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands? at Motley Fool
Feb-16-17 09:40PM  Shkreli defends drug prices, spars with protesters at heated UMass Boston event at
09:37PM  Tesaro sees a $5B market opportunity for its cancer drug at
09:27AM  Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
Feb-15-17 07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? at Motley Fool
05:29PM  Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference Business Wire
04:18PM  Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next?
10:46AM  Merck Halts Late-Stage Alzheimers Drug Trial at Investopedia
07:18AM  Bioverativ's hemophilia hopes
07:00AM  Another Alzheimer's Drug Study Fails. This Time It's Merck's. at Forbes
Feb-13-17 03:52PM  Key Presenters At Leerink's Healthcare Conference
02:25PM  Regeneron: It's All Riding On Dupixent at
09:00AM  Biogens Spinraza Faces Insurance Coverage Hurdles at Investopedia
Feb-12-17 07:43AM  A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease at Motley Fool
Feb-10-17 04:14PM  Is Biogen a Risky Stock? at Motley Fool
09:55AM  Major Biotechs Scare Off Loads of Short Sellers
08:38AM  Biotech ETFs Powered by Q4 Earnings
Feb-09-17 09:05AM  Humana to limit coverage of pricy Biogen drug at
Feb-08-17 05:31PM  What's Behind Bioverativ's Spin-Out, and Should You Buy? at Motley Fool
01:04PM  BIOGEN INC. Financials
06:45AM  Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib
Feb-07-17 04:53PM  Biogen's Slow Rebound Prompts A Vetr Downgrade
04:20PM  Caterpillar, Biogen, CSX, Big-Box Stores In Analyst Crosshairs
04:01PM  Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference Business Wire
09:04AM  The Market In 5 Minutes: GM And Gap Earnings, Retail Sales Data
08:30AM  In an Ironic Twist, Generics Take Aim at Teva Pharmaceutical at Motley Fool
06:46AM  Biogen upgraded by Citigroup
Feb-06-17 10:41AM  Chardan Analyst Suggests An AveXis-Ionis Pair Trade
08:45AM  Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
Feb-03-17 03:55PM  Biogen Faces Federal Probes for Drug Prices, Rebates at Investopedia
11:03AM  Why Forward Pharma A/S Stock Surged 107% in January at Motley Fool
05:55AM  Hunting down the years 5 hottest M&A targets at MarketWatch
Feb-02-17 05:55PM  Biogen Reveals Federal Investigation Into Pricing, Rebate Payments -6.20%
05:32PM  Biogen: What Now? at
05:09PM  Biogen subpoenaed by federal government over MS drug prices at
04:51PM  Biogen Trails Merck, Lilly In Alzheimer's; Hemophilia Spinoff Begins Trading
03:54PM  [$$] Bioverativ: New Spinoff and Attractive Target at
12:30PM  ETFs with exposure to Biogen, Inc. : February 2, 2017
11:13AM  Biogen Cancels Autoimmune Drug Deal With Tanabe at Investopedia
10:40AM  5 Drugmakers Battle Over the $10 Billion Hemophilia Market at Motley Fool
08:02AM  What Could Make Biogen Crash? at Motley Fool
07:35AM  Understanding Celgenes Operational Performance Projections for 2017
06:27AM  Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
Feb-01-17 08:52AM  Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN
07:38AM  Biogen's hemophilia business spin-off will trade on its own starting Thursday at MarketWatch
07:30AM  Biogen Completes Separation of Global Hemophilia Business, Bioverativ Business Wire
Jan-31-17 11:15AM  Biogens hemophilia spinoff launches this week. Heres what you need to know. at
10:37AM  Spinraza: First Approved Therapy for Spinal Muscular Atrophy in the US
09:45AM  Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence
09:08AM  Biosimilar Segment May Drive Biogens Revenue Growth
07:39AM  Tysabri Witnessed Robust Growth in the Number of Patients in 2016
Jan-30-17 05:06PM  Biogen Continues Its Dominance in the Multiple Sclerosis Segment
03:28PM  Biogen Reported Modest Revenue Growth in 4Q16
02:36PM  Celgenes Financial Performance in 2016: Strong Growth in Volumes
09:43AM  Biogen, Inc. :BIIB-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017
09:30AM  The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean
Jan-27-17 02:28PM  Biogen Inc Makes Up for Lackluster Revenue Growth at Motley Fool
01:22PM  Q4 Scorecard and Analyst Reports for AT&T, Biogen & Qualcomm
10:45AM  Biogen 4Q Net $2.99 a Share Vs $3.77 Last Year at Investopedia
Jan-26-17 04:47PM  Biogen Sidesteps Q4, 2016 Sales Misses On Strong Ex-Hemophilia Guide
02:50PM  Edited Transcript of BIIB earnings conference call or presentation 26-Jan-17 1:00pm GMT
01:21PM  Biotech ETFs: Is It Time To Buy? at
12:50PM  Biogen Rallies Despite Mixed Revenue Guidance
10:15AM  Biogen earnings lift shares, but concerns about multiple sclerosis drug sales persist at
09:50AM  Why Biogen is Flying at
09:32AM  Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
08:05AM  Biogen MS Drug Tecfidera Gets Liver Injury Warning at Investopedia
08:03AM  Early movers: CMCSA, F, LUV, CAT, PHM, BIIB & more at CNBC
08:00AM  Biogen (BIIB) Beats on Q4 Earnings; Misses Sales
07:07AM  Q4 2016 Biogen Inc Earnings Release - Before Market Open
07:01AM  3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000 at Motley Fool
07:00AM  [$$] Biogen Profit Skids, Revenue Grows Less Than Expected at The Wall Street Journal
06:45AM  Biogen tops 4Q profit forecasts
06:41AM  Biogen profit drops 22 pct due to Tecfidera-related costs
06:37AM  Biogen Profit Beats Estimates as CEO Takes the Helm at Bloomberg
06:35AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition
06:30AM  Biogen Reports 2016 Revenues of $11.4 Billion Business Wire
Jan-25-17 03:47PM  5 Stocks to Watch Before the Market Opens Tomorrow
02:30PM  What to look for when Biogen reports earnings on Thursday at
02:29PM  Possible liver injury added to label of Biogen MS drug Reuters
11:51AM  Bristol-Myers Squibb May Report Strong Revenue Performance for 2017
11:25AM  What to Expect From Major Health Care Stocks Reporting This Week
10:26AM  Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA
09:08AM  Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY
06:59AM  Earnings Preview: What To Expect From Biogen On Thursday at Forbes
Jan-24-17 06:10PM  LogMeIn and Bioverativ Set to Join the S&P MidCap 400; Others to Join S&P SmallCap 600 PR Newswire
05:42PM  Better Buy: Biogen Inc. vs. Gilead Sciences Inc. at Motley Fool
08:47AM  Top Biosimilar Drug Companies at Investopedia
Jan-23-17 01:30PM  [video]5 Reasons Celgene Should Buy Biogen
12:40PM  Celgene Estimates Robust Revenue in 2017
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM